REGENXBIO to Present at the 28th Annual Piper Jaffray Healthcare Conference

ROCKVILLE, Md., Nov. 17, 2016 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated (AAV) gene therapy based on its proprietary NAV® Technology Platform (NAV), today announced that President and CEO Kenneth T. Mills will present as part of the Gene Therapy Panel at the 28^th Annual Piper Jaffray Healthcare Conference. The panel will take place on Wednesday, November 30, 2016 at 10:00 a.m. ET at the Lotte New York Palace in New York City. In addition, REGENXBIO representatives will be holding one-on-one meetings at the conference.

About REGENXBIO

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of September 30, 2016, REGENXBIO’s NAV Technology Platform was being applied in the development of 29 product candidates for a variety of diseases, including five internally developed candidates and 24 partnered candidates developed by REGENXBIO’s licensees.

Investors
Heather Savelle, 646-395-3734
[email protected]

Media
Laura Bagby, 312-448-8098
[email protected]